Yttrium-90 microsphere radioembolization for hepatocellular carcinoma - Université de Rennes Access content directly
Journal Articles Liver Cancer Year : 2015

Yttrium-90 microsphere radioembolization for hepatocellular carcinoma

Abstract

Yttrium-90 (Y90) radioembolization is an emerging strategy to treat liver malignancies, and clinical data supporting its use have accumulated in recent years. Y90-radioembolization has shown clinical effectiveness in intermediate and advanced hepatocellular carcinoma, with a favorable safety profile. Retrospective data show similar levels of effectiveness to transarterial chemoembolization in intermediate hepatocellular carcinoma, with some evidence of better tolerance. While phase 3 studies comparing Y90-radioembolization to chemoembolization in intermediate hepatocellular carcinoma would be difficult to conduct, studies comparing or combining Y90-radioembolization with sorafenib are under way. Questions also remain about the most suitable modalities for defining the dose to administer. Phase 3 studies are under way to clarify the place of Y90-radioembolization in the algorithm of HCC treatment

Dates and versions

hal-01162379 , version 1 (10-06-2015)

Identifiers

Cite

Julien Edeline, Marine Gilabert, Etienne Garin, Eveline Boucher, Jean-Luc Raoul. Yttrium-90 microsphere radioembolization for hepatocellular carcinoma. Liver Cancer, 2015, 4 (1), pp.16--25. ⟨10.1159/000343878⟩. ⟨hal-01162379⟩
87 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More